Sustained improvement of clinical status and pulmonary hypertension in patients with severe heart failure treated with sildenafil

Annals of Transplantation

Volumn 19, Issue 1, 2014, Pages 325-330

  Urbanowicz, Tomasz ^a   Straburzyńska Migaj, Ewa ^a   Katyńska, Izabela ^a   Araszkiewicz, Aleksander ^a   Oko Sarnowska, Zofia ^a   Grajek, Stefan ^a   Jemielity, Marek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cardiac catheterization; Heart failure; Phosphodiesterase 5 inhibitors; Vascular resistance

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SILDENAFIL; SPIRONOLACTONE;

ADULT; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CLINICAL EVALUATION; DIARRHEA; ECHOCARDIOGRAPHY; EVALUATION AND FOLLOW UP; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEART CATHETERIZATION; HEART FAILURE; HEART INDEX; HEARTBURN; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG GAS EXCHANGE; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PROSPECTIVE STUDY; PULMONARY HYPERTENSION;

ADULT; CARDIAC CATHETERIZATION; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY WEDGE PRESSURE; PURINES; SEVERITY OF ILLNESS INDEX; SULFONES; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 84904296339     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.890657     Document Type: Article

References (32)

1. Stelken AM, Younis LT, Jennison SH et al: Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol, 1996; 27: 345-52
2. Hosenpud JD, Bennett LE, Keck BM et al: The registry of the international society for heart and lung transplantation: seventeenth official report - 2000. J Heart Lung Transplant, 2000; 19: 909-31
3. Alaeddini J, Uber PA, Park MH et al: Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol Dec, 2004; 94(11): 1475-77
4. Chen J.M, Levin HR, Michler RM et al: Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiov Sur, 1997; 114: 627-34
5. Costard-Jäckle A, Fowler MB: Influence of perioperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining high risk group. J Am Coll Cardiol, 1992; 19: 48-54
6. Delegado JF, Gomez-Sanchez MA, Saenz de la Calzada C et al: Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. J Heart Lung Transplant, 2001; 20(9): 942-48
7. Deng MC, Gradaus R, Hammel D et al: Heart transplant candidates at high risk can be identified at the time of initial evaluation. Transplant Int, 1996; 9: 38-45
8. Beaver WL, Wasserman K, Whipp BJ: A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol, 1986; 60: 2020-27
9. Murali S, Kormos RL, Uretsky BF et al: Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J, 1993; 126: 896-904
10. Angel Gomez-Sanchez M, Saenz De La Calzada C, Escribano Subias P et al. Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. Eur J Heart Fail, 2004; 6(5): 615-17
11. Steinman TI, Becker BN, Frost AE et al: Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation, 2001; 71: 1189-204
12. Boyle A, Colvin-Adams M: Recipient selection and management. Semin Thorac Cardiovasc Surg, 2004; 16: 358-63
13. Costanzo MR, Augustine S, Bourge R et al: Selection and treatment of candidates for heart transplantation: A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation, 1995; 92: 3593-612
14. Rabe KF, Tenor H, Dent G et al: Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol, 1994; 266: L536-43
15. Michelakis E, Tymchak W, Lien D et al: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation, 2002; 105: 2398-403
16. Lewis GD, Shah R, Shahzad K et al: Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation, 2007; 116(14): 1555-62
17. Katz SD, Balidemaj K, Homma S et al: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol, 2000; 36: 845-51
18. Guazzi M, Tumminello G, DiMarco F et al: Influences of Sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther, 2004; 76: 371-78
19. Koike A, Wasserman K, Taniguichi K et al: Critical capillary oxygen partial pressure and lactate threshold in patients with cardiovascular disease. J Am Coll Cardiol, 1994; 23: 1644-50
20. Guazzi M, Samaja M, Arena R et al: Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol, 2007; 50: 2136-44
21. Guazzi M, Vicenzi M, Arena R et al: PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure. Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study. Circulation: Heart Failure, 2011; 4: 8-17
22. Redfield MM, Chenn HH, Semigran MJ et al: Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. Relax trial. JAMA, 2013; (12): 1268-77
23. Guazzi M, Tumminello G, Di Marco F et al: The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol, 2004; 44: 2339-48
24. Schofield RS, Edwards DG, Schuler BT et al: Vascular effects of sildenafil in hypertensive cardiac transplant recipients. Am J Hypertens, 2003; 16: 874-77
25. Guimaraes GV, d'Avila VM, Pires P et al: Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-h ambulatory blood pressure monitoring in heart transplant recipients. Transplant Proc, 2007; 39: 3142-49
26. Boffini M, Sansone F, Ceresa F et al: Role of Oral Sildenafil in the Treatment of Right Ventricular Dysfunction After Heart Transplantation. Transplantation Proc, 2009; 41(4): 1353-56
27. Kryczka K, Dzielinska Z, Przybylski A et al: Therapeutic challenges and management of heart failure during pregnancy (part I). Med Sci Monit, 2012; 18(5): CQ5-7
28. Kryczka K, Dzielinska Z, Przybylski A et al: Therapeutic challenges and management of heart failure during pregnancy (part 2). Med Sci Monit, 2012; 18(6): CQ9-13
29. Karatza AA, Bush A, Magee AG: Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. INT J Cardiol, 2005; 100: 267-73
30. Travadi JN, Patole SK: Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review. Pediatric Pulmonology, 2003; 36(6): 529-35
31. Kulkarni A, Singh TP, Sarnaik A et al: Sildenafil for pulmonary hypertension after heart transplantation. J Heart Lung Transplant 2004;23: 1441-44
32. Pons J, Leblanc MH, Bernier M et al: Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation. J Heart Lung Transplant, 2012; 31(12): 1281-87